Zydus Lifesciences has received USFDA priority review for its liver disease drug Saroglitazar, with a decision expected by November 2026. The company also recently completed its $166.4 million acquisition of Assertio Holdings to strengthen its US oncology and specialty business. These developments, coupled with efforts to help address US oncology drug shortages, are central to the company’s growth outlook for fiscal year 2027.
What Happened
Zydus Lifesciences has marked two significant milestones in its US operations. First, the US Food and Drug Administration (USFDA) has granted priority review to the company's New Drug Application (NDA) for Saroglitazar magnesium. This drug is intended to treat Primary Biliary Cholangitis (PBC), a chronic liver disease. The FDA has set a target action date of November 27, 2026, for its decision. Second, the company has successfully completed the $166.4 million acquisition of Assertio Holdings. This strategic move is designed to scale Zydus’s commercial presence in the US specialty oncology and neurology markets.
The US Specialty Pivot
The acquisition of Assertio Holdings is a key part of Zydus’s shift toward a hybrid specialty-generic business model. By acquiring Assertio, Zydus gains an established commercial platform in the US, which it plans to use to expand the reach of products like Rolvedon, a biologic treatment for chemotherapy patients. For investors, this move is significant because it aims to reduce the company's dependence on price-sensitive generic drugs by entering higher-margin specialty therapeutic areas. The company expects the integration to broaden its addressable market and strengthen its direct-to-specialist marketing capabilities.
Liver Drug Pipeline Update
Saroglitazar remains a cornerstone of the company’s innovation strategy. The priority review status highlights the drug's potential clinical importance, as the designation is reserved for therapies that may offer significant improvements in safety or effectiveness for serious conditions. If the FDA approves the drug by the target date in November 2026, Zydus plans to launch the product in the US market during the fourth quarter of fiscal year 2027. However, the company will face competition from established therapies offered by global players like Gilead and Ipsen, making successful market entry and product uptake critical for realizing the drug’s commercial potential.
Addressing US Oncology Shortages
Zydus is also gaining investor attention due to ongoing supply constraints in the US chemotherapy market. Reports indicate that the US FDA has reached out to Indian manufacturers, including Zydus, to explore potential supplies of ifosfamide, a critical chemotherapy drug facing shortages due to manufacturing disruptions in the US. While no specific supply contracts have been confirmed, Zydus’s established presence in the oncology injectable space and its regulatory track record position it as a potential alternative supplier. This situation underscores the company's manufacturing flexibility, though it remains an opportunistic contributor to revenue rather than a guaranteed long-term trend.
Capex And Financial Targets
To support these growth initiatives, Zydus has outlined an aggressive capital expenditure plan of ₹1,500 crore for fiscal year 2027. The company is prioritizing investments in both new capacity and commercialization efforts for its pipeline. Management has provided guidance for high-teen percentage revenue growth in FY27, with an expectation that the Indian branded formulations business will continue to outperform the broader domestic pharmaceutical market. The company also aims to maintain EBITDA margins above 24%, balancing the costs of launching new drugs like Saroglitazar with operational efficiency.
What Investors Should Track
Investors may monitor several key developments: the FDA’s final decision on Saroglitazar in November 2026, the progress of integrating Assertio’s operations into the existing US business, and the company's ability to maintain its margin guidance amid capital spending. Additionally, any updates regarding supply agreements for oncology drugs in the US and the progress of other pipeline candidates will be important to watch.